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Abstract 
Cervical cancer is one of the leading causes of death from cancer around the world, resulting 
in nearly 300,000 deaths each year (Torre et al., 2012). Infection with high risk types of Human 
Papillomavirus is the primary etiologic event associated with the development of cervical cancer 
(Wallboomers, 1999). Since 2006, HPV vaccines have dramatically decreased cases of cervical 
cancer in developed countries. However, because these vaccines are expensive and require cold 
chain storage, their use in developing countries, where 85% of deaths from cervical cancer occur, 
has been limited (Torre et al., 2012; Kane, 2006). Development of second generation HPV 
vaccines that are inexpensive and thermodynamically stable at high temperatures is necessary to 
expand access to HPV vaccines to regions where they are needed the most.   
The research project described in this thesis details the characterization of monoclonal 
antibodies specific to the L1 capsid protein of Human Papillomavirus type 45. The monoclonal 
antibodies were developed at NeoClone, then tested in three laboratory assays: enzyme linked 
immunosorbent assays (ELISAs), Western blots and pseudovirus neutralization assays. 
Identifying monoclonal antibodies specific to HPV45 L1 in each of these assays is important for 
the design and production of second-generation HPV vaccines.  
During characterization, it was determined that the monoclonal antibodies were reactive 
toward a cross contaminant instead of HPV45 L1. Although the antibodies are contaminated, this 
thesis serves as a proof of concept for the characterization of HPV45 L1 monoclonal antibodies 
and can be used as a roadmap in further characterization experiments.  
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1. Introduction 
Cervical cancer is the fourth most common cancer in women worldwide, with over 
528,000 cases recorded in 2012 (Ferlay et al., 2015). In the US, where cervical cancer is the 
eighth most common cancer among women, the five year survival rate is 68% (Howlader et al., 
2013). In developing countries that lack widespread screening programs and prevention methods, 
the survival rate is much lower. Of the 266,000 deaths from cervical cancer in 2012, 85% 
occurred in developing countries (Torre et al., 2012). Because cervical cancer is most prevalent 
among young women, it is the largest cause of years of life lost due to cancer in the developing 
world (Agosti et al., 2007). This disparity is largely due to the lack of screening programs or 
accessible vaccines, two measures that reduce cases of cervical cancer by 80% (Schiller, 2012; 
Denny, 2006).  
The persistence of HPV DNA is the primary etiologic event associated with cervical 
cancer and has been found to be necessary for the development of 99% of all cervical cancers. 
(Bosch, 2002; Wallboomers, 1999). HPV is a non-enveloped, double stranded DNA virus that 
infects the stratified squamous epithelium (Schiller, 2012). The virus has a T7, right handed 
icosahedral structure made of 72 pentameric subunits that each consist of five interconnected L1 
proteins (Chen, 2000, Baker 1991). Out of the 100 HPV types that have been identified, 40 can 
infect the genital tract and 15 are considered to be ‘high risk’ because they are associated with 
progression to carcinoma of the cervix, vulva, vagina, penis, anus and oropharynx (Munoz, 
2003). ‘Low risk’ HPV types are associated with sexually transmitted genital warts as well as 
hand and foot warts (Garland et al., 2009; Iftner et al., 2003).  
 The development of HPV vaccines for the prevention of cervical cancer began in 1990 
after the discovery that L1, the major capsid protein, can spontaneously self-assemble into a 
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capsid when expressed in certain cell systems (Kimbauer et al., 1993). The virus like particles 
(VLPs) produced by the self-assembly of L1 proteins resemble native virions and generate a 
humoral immune response that is directed against conformation epitopes on the L1 capsid 
protein (Stanley et al., 2006). One of the earliest vaccines, Cervarix® made by GlaxoSmithKline 
Biologicals, is produced using a baculovirus vector and contained VLPs for  HPV type 16 and 18 
which account for 70% of high risk HPV infections in the US (Stanley et al., 2006). Another 
early vaccine, Gardasil® made by Merck, is produced using a Saccharomyces pombe vector and 
contains VLPs for HPV types 6, 11, 16 and 18 (Stanley et al., 2006). The most recently 
developed vaccine, Gardasil 9®, contains VLPs from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 
58 which account for 90% of all HPV infections (Joura et al., 2015). While these vaccines are 
effective prophylactic measures, they are only accessible in developed countries where deaths 
from cervical cancer are already dramatically reduced from effective screening programs 
(Schiller, 2012). These vaccines cost over $4.00 per vaccine to produce and are sold at $120 per 
dose in the United States. In addition, the vaccines require cold chain storage. Both the cost and 
storage requirements severely limit the use of these vaccines in developing countries. A second 
generation HPV vaccine that is low cost, single dose and does not require cold-chain storage is 
necessary to make prophylactic HPV prevention more accessible around the world.  
To reduce the cost of vaccine production, second generation vaccines that use individual 
pentameric subcapsid particles instead of VLPs are being researched. These vaccines can be 
produced in Escherichia coli, a less expensive expression system (Gersch, 2012). While the 
VLPs need a cell nucleus in order to self-assemble, L1 proteins will spontaneously form 
pentamers, the base subunits of the HPV capsid, in bacteria (Thones et al., 2008). Protein 
pentamers initiate a similar immune response to VLPs when combined with adjuvants such as 
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monophosphoryl lipid A adsorbed to aluminum hydroxide (Yuan, 2001; Wu, 2011; Thones et al., 
2008). In order to remove the need for cold-chain storage, these pentameres can be lyophilized, a 
process where the L1 capsomeres are embedded in glassy matricies at extremely high pressures 
to produce a dry, thermally stable powder vaccine (Hassett et al., 2015).  
The Garcea Lab at the University of Colorado at Boulder is currently working to produce 
a quadravalent, second generation HPV vaccine that protects against HPV types 16, 18, 31 and 
45. This vaccine uses L1 capsomeres expressed in E. coli to reduce production costs. In addition, 
the HPV type 16 L1 capsomeres have been shown to be thermally stable with lyophilization 
without reduced immunogenicity (Hassett et al., 2015). In order to ensure consistency and 
quality control in vaccine production, reactive antibodies have been characterized for three of the 
HPV types incorporated into this vaccine, types 16, 18 and 31. This research project seeks to 
characterize monoclonal antibodies specific for HPV type 45. To create an antibody set unique 
for HPV 45 L1, the protein was expressed in E. coli cells, purified using column 
chromatography, then sent to a monoclonal facility (NeoClone, Madison, WI) where it was 
injected into mice. Cells producing antibodies to the protein were fused with hybridoma cells and 
subcloned, creating a wide range of monoclonal antibodies that were sent back to Boulder for 
testing in Western blots, enzyme-linked immunosorbent assays (ELISAs), and pseudovirus 
neutralization assays. The goal was to determine which antibodies should be used to identify 
HPV45 L1 in future vaccine development and experiments. However, due to a contamination in 
the production of the monoclonal antibodies of an unknown source, the antibodies were not 
reactive towards HPV 45 L1. This paper will provide an overview of the characterization of 
these monoclonal antibodies and serve as a template for future characterization protocols.  
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2. Materials and Methods  
All research was conducted in the Garcea Lab at the University of Colorado at Boulder with the 
exception of section 2.2 which was completed by NeoClone.  
 
2.1 HPV45 L1 Production  
BLR DE3 E. coli were heat transformed with a plasmid containing kanamycin resistance 
gene and a gene encoding HPV45 L1 linked to a lac operon promoter. Transformed cells were 
then plated onto luria broth (LB) media plates with kanamycin incubated at 37oC overnight to 
select for transformed colonies. Single colonies were inoculated into 3 ml of Terrific broth (TB) 
containing 50 µg/ml kanamycin diluted 1:1000 and grown for 6 hours at 30oC with shaking. 200 
µl of this culture was then inoculated into 50 ml of TB containing 50 µg/ml kanamycin and 
grown overnight at 30oC with shaking. Two milliliters of the culture was inoculated into 6 
baffled flasks each containing 500 ml TB with 50 µg/ml kanamycin for three liters total culture. 
The baffled flasks were incubated at 37oC with shaking until the optical density at 600 nm 
reached 4.0. The flasks were then chilled to 25oC in an ice water bath. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Research Products International, Mount Prospect, IL) was added 
to the culture to a final concentration of 0.2 mM to initiate HPV45 L1 expression. The induced 
culture was incubated at 25oC with shaking until the optical density at 600 nm reached 8.0. The 
culture was pelleted by centrifugation at 5,800 x g for 15 minutes at 4oC and stored at -20oC 
overnight.   
 For purification, the frozen bacteria pellets were each resuspended in 50 ml 
homogenizing buffer (200 mM NaCl, 50 mM Tris, pH 8.0, 1mM EDTA, 1mM PMSF, 10% 
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glycerol, 0.01% Tween 80, 5 mM DTT, pH 8.1) with stirring at 4oC. Once resuspended, the cells 
were lysed using a Panda homogenizer between 800-1000 bar. After one pass through the 
homogenizer, the lysate was cooled to 4oC with stirring, then passed through the Panda 
homogenizer a second time. The lysate was centrifuged at 22,000 x g for 30 minutes at 4oC 
which pelleted out insoluble bacterial proteins and cell debris (P1), leaving the L1 protein in the 
soluble fraction (S1). The S1 was run through a 300 ml Q Sepharose Fast Flow (QFF) (GE 
Healthcare, Piscataway, NJ) column equilibrated with running buffer (200 mM NaCl, 50 mM 
Tris, 10% glycerol, 5 mM DTT, pH 8.1). Ammonium  sulfate was added to the flow through 
(30% saturation) and stirred for two hours at 4oC in order to precipitate out the L1 protein. The 
solution was centrifuged at 13,000 x g for 30 minutes and the resulting pellet (AS-P) was stored 
at 4oC overnight.  
 The pellet containing the L1 protein (AS-P) was resuspended in 10 mL Running Buffer 
(25mM NaCl, 50 mM Tris, 10% glycerol, 5 mM DTT, pH 8.5), passed through the Panda 
homogenizer at 500 bar, and centrifuged at 13,000 x g for 20 minutes. The conductivity and pH 
of the soluble fraction were adjusted to match the Running buffer using no-salt buffer (50 mM 
Tris pH 8.5, 5 mM DTT, 10% glycerol, pH 8.5). A 75 ml Q Sepharose High Performance 
column (QHP) (GE Healthcare, Piscataway, NJ) was equilibrated with Running buffer and the 
soluble fraction containing L1 was loaded onto the column. The L1 protein bound to the column 
and then was eluted over an increasing NaCl concentration gradient from 25 mM to 1 M NaCl 
Running buffer. The eluted fractions were analyzed using 10% Sodium Dodecyl Sulfate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) to determine which fractions contained the L1 
protein (52 kD). L1 containing fractions were then pooled, quantified, flash frozen in liquid 
nitrogen and stored at -80oC.  
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2.2 Monoclonal Antibody Production 
 HPV 45 L1 protein purified in section 2.1 was sent to NeoClone for monoclonal antibody 
production. Over the course of three months NeoClone conducted three fusions. The antibodies 
produced by each fusion were screened with ELISAs by NeoClone then sent to Boulder for 
confirmation of positive clones. 42 total antibody-producing hybridoma cell lines were selected 
through this process. Antibodies from these lines were purified using protein affinity 
chromatography and aliquots were shipped back to Boulder for analysis using ELISA, Western 
blots and pseudovirus neutralization assays.  
 
2.3 Enzyme-Linked ImmunoSorbent Assays (ELISA)  
 Serial dilutions of HPV45 L1 in 1x Phosphate-Buffered Saline (PBS) were added to a 
Polysorp 96 well plate (Nunc, Naperville, IL) with a final dilution of 0.25 µg, 0.13 µg and 0.06 
µg of protein per well, each concentration was run in duplicate. A fourth well had no protein and 
served as a negative control. Each well had a final volume of 50 µl. The plate was covered with 
parafilm and left at 4oC overnight to allow the protein to bind to the wells.  
 After binding overnight, the plates were washed three times with 50 µl per well Wash 
Buffer (1X PBS, 0.05% Tween20) and 100 µl per well of Block Buffer (5% non-fat dry milk in 
wash buffer) was added. The plates were incubated for one hour at 37oC, then the Block Buffer 
was removed and 50 µl/well of each primary monoclonal antibody diluted 1:1000 in Wash 
Buffer was added. Positive controls were primary anti L1 antibodies and anti V5 monoclonal 
antibodies against L1 protein and conformationally correct HPV16 respectively. Negative 
controls were HPV45 L1 and a murine polyomavirus VP1 (MPyV VP1) structural protein 
against the anti V5 antibody. The plates were incubated at 37oC for one hour, then washed three 
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times with 50 µl/well Wash Buffer. Fifty µl/well of anti-mouse horseradish peroxidase (HRP) 
conjugated IgG secondary antibodies diluted 1:5000 in Wash Buffer was added to all wells 
except where the anti L1 antibody was used. Fifty µl/well of anti-rabbit horseradish peroxidase 
conjugated IgG secondary antibodies diluted 1:5000 in Wash Buffer was added to wells where 
the L1 antibody was used. The plates were incubated at 37oC for one hour. After incubation, the 
plates were washed three times with 50 µl/well Wash Buffer and 50 µl/well of TURBO 3,3’ ,5’5-
Tetramethylbenzidine (TMB) substrate (Thermo Scientific, Waltham, MA) was added. After five 
minutes the wells turned sufficiently blue and 50 µl/well 1M sulfuric acid was added to stop the 
reaction. Absorbance values were read using an ELx808 absorbance reader (Bio Tek, Winooski, 
VT) at a wavelength of 450 nm.  
 
2.4 Western Blots 
 HPV45 L1, HPV16 L1 and MPyV VP1 at a concentration of 0.1625 µg/lane was run on a 
10% SDS-PAGE (150 V, 500 mA, 75 minutes). HPV16 L1 and MPyV VP1, BLR cell lysate 
(BLR) and uninduced cell lysate (BLR cells + HPV45 L1 plasmid) were run to test for cross-
reactivity. The gel was washed for ten minutes in Transfer Buffer (250 mM Tris, 2 M glycine), 
then transferred to a nitrocellulose membrane using a Hoefer IE70 Semi-dry Transfer Unit 
(Amersham Biosciences, Madison , WI) set at 15 V, 500 mA for 45 minutes. The membrane was 
blocked overnight in Block Buffer at 4oC or for one hour at room temperature (TBST; 5% milk 
in Tris-buffered Saline, Tween20).  
 After blocking, the membrane was washed three times for 5 minutes each with Tris-
buffered Saline, Tween20 (TBST). A primary antibody solution consisting of one HPV45 L1 
monoclonal antibody diluted 1:1000 in TBST was added to the membrane and rocked at room 
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temperature for one hour. The membrane was then washed three times for 5 minutes each with 
TBST, and a secondary antibody solution consisting of goat-α-mouse-alkaline phosphatase 
antibody diluted 1:5000 in TBST was added. After rocking for an hour at room temperature, the 
membrane was washed three times for five minutes each with TBST and 20ml of developer 
consisting of BCIP (5-bromo-4-chloro-3’-inolyphosphate-p-toluidine) and NBT (nitro-blue 
tetrazolium chloride) in a 1X alkaline phosphatase (AP) developing solution (0.4 M Tris, 1 M 
NaCl, 0.2 M MgCl2) was added and the blot was left to develop for 5 minutes. The membrane 
was rinsed in water, and allowed to air dry.  
 
2.5 Pseudovirus Neutralization Assays  
 293T augmented cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; 
supplemented with 10% Fetal bovine serum (FBS), 1% Antimicrobial-Antimycotic, 1% MEM, 
1% Glutamax) with routine passaging at 80-90% confluency. After two passages, the cells were 
washed with PBS, trypsinized and counted. They were then centrifuged at 2000 x g for 5 minutes 
and resuspended in DMEM minus phenol red (DMEM-PR) with a final concentration of 3x105 
cells/ml. One hundred µl/well of this suspension was added to the internal wells of a Greiner 
CellStar 96-well cell culture plate. One hundred fifty µl/well DMEM was added to the exterior 
wells to prevent evaporation from interior wells. The plate was covered and incubated for 2 
hours at 37oC. In a round-bottom 96 well plate, six serial dilutions (1:80, 1:320, 1:1280, 1:5120, 
1:20480, 1:81920) of HPV45 L1 monoclonal antibodies in supplemented DMEM-PR were added 
to a final volume of 50 µl/well for the lowest dilution and 40 µl/well for all other dilutions.  
 In a new round-bottom 96 well-plate, HPV45 pseudovirus (containing a Secreted 
Embryonic Alkaline Phosphatase (SEAP) reporter plasmid) at a dilution of 1:250 in DMEM-PR 
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was added to a final volume of 120 µl/well using siliconized pipet tips. Thirty µl/well from the 
monoclonal antibody dilution plate was added to the pseudovirus plate using siliconized tips. 
Anti Bovine Papillomavirus (BPV) antibody diluted 1:50 in DMEM-PR was used as a negative 
neutralization control. 1 mg/ml heparin was used as a positive neutralization control. The 
background control consisted of wells containing only 293TT cells in DMEM-PR. The 
pseudovirus/antibody mix was left for one hour on ice, then 100 µl/well of the 
pseudovirus/antibody mix was added to the plated 293TT cells and the plate was incubated at 
37oC for 72 hours.  
 After incubating for 72 hours, 50 µl of cell media per well was removed and placed in a 
new round-bottom 96 well plate and centrifuged for 5 minutes at 1000 x g. In a Costar white 96-
well optiplate, 45 µl/well of 1x Dilution Buffer (Great Escape Chemiluminescence Detection Kit 
2.0) and 15 µl/well of clarified supernatant was added. The optiplate was sealed and wrapped in 
coverfoil, then incubated at 65oC for 30 minutes. After incubation, the optiplate was chilled for 3 
minutes on ice, then brought to room temperature. Sixty µl/well chemiluminescence substrate (4-
methylumbelliferyl phosphate, MUP) from the detection kit was added and allowed to incubate  
for one hour at room temperature. After the hour, the optiplate was read for chemiluminescence 
values in a Synergy 2 Multi-mode plate reader (BioTek, Winooski, VT).  
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3. Results  
The results reported below were obtained in the Garcea Lab at the University of 
Colorado, Boulder. Experiments characterizing HPV45 L1 monoclonals were conducted from 
October, 2015 through February, 2016. Because the HPV45 L1 monoclonal antibodies made by 
NeoClone were found to cross react with a contaminant after testing with ELISA and Western 
blots, the monoclonal antibodies were not tested for reactivity in a pseudovirus neutralization 
assay.  Results for the pseudovirus neutralization assay were obtained using sera from mice 
injected with purified HPV45 L1 capsomeres as a proof of concept. 
 
3.1 ELISAs 
 All 42 monoclonal antibodies were tested for reactivity in ELISAs (Fig. 1). Reactivity 
was assessed using absorbance values for the wells containing each monoclonal with higher 
absorbance values reflecting higher reactivity of the monoclonal antibody to the HPV45 L1 
protein. Positive controls were anti L1 antibodies which bound to HPV45 L1 and anti V5 
antibodies which bound to HPV16 L1. Negative controls were anti V5 antibodies which did not 
recognize HPV45 L1 or MPyV VP1. Absorbance values ranged from 0 relative absorbance units 
(RAU) to 2.744 RAU. 14 of the monoclonal antibodies were reactive in the ELISA with 
absorbances above 0.5 RAU. 4 antibodies were strongly reactive with an absorbance above 2 
RAU.  
 
3.2 Western Blots 
 All 42 of the HPV45 L1 monoclonal antibodies were tested for reactivity in Westerns 
(Fig. 2). Visible banding on the Western blots was used as an indication that the monoclonal 
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antibodies identified and bound to HPV45 L1 on the blot. This banding was the result of a 
reaction between the developer and the alkaline phosphatase (AP) enzyme on the secondary 
antibody. In this reaction, the alkaline phosphatase enzyme hydrolyzes BCIP in the developer to 
a form that is oxidized by NBT, creating a dark blue diformazan precipitate visible on the 
membrane. If the monoclonal antibody is reactive to proteins on the membrane, then the 
antibody binds to those proteins. The secondary anti mouse-AP antibodies are then able to bind 
to the primary monoclonal antibody, providing AP for the developer reagents to react with. If the 
monoclonal antibody is not reactive to proteins present on the blot, then there is no initial 
binding of primary antibody and no subsequent binding of the secondary antibody leading to no 
visible banding on the blot.  
Prior to initiation of the Western blots, the purified HPV45 L1 was run on a coomassie 
gel to determine the size of the L1 monomer (Fig. 3A). In the gel, as with previous studies on 
HPV L1, the protein was visualized in a band at ~55 kDa. In the first 14 Western blots, however, 
there were no bands visualized at 55 kDa. Instead, the monoclonal antibodies reacted with 
proteins at ~100 kDa and <55 kDa, neither of which had visible bands on the coomassie. To 
determine if the monoclonals were contaminated with proteins from the BLR E. coli cells used to 
express the HPV45 L1 protein, the six monoclonal antibodies that were found to be reactive in 
the initial Western blots and all subsequent monoclonal antibodies were tested for reactivity in 
Western blots that also contained BLR cell lysate (BLR) and uninduced cell lysate (BLR cells + 
HPV45 L1 plasmid) (BLR+plasmid) (Fig. 3B). In addition, positive controls of anti L1 antibody 
and the Gardasil sera antibody (reactive toward HPV45 L1 and HPV16 L1) were tested for 
reactivity against HPV45 L1, MPyV VP1, HPV16 L1, BLR and 45un. As expected, the anti L1 
reacted with the L1 monomer at ~55 kDa in the HPV45 L1 lane, the HPV16 L1 lane, the BLR 
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lysate and the BLR+plasmid (Fig 3B). The more specific Gardasil antibody reacted with the L1 
protein in both the HPV45 lane and the HPV16 lane (Fig 3c).   
 
3.3 Pseudovirus Neutralization Assay  
Because the monoclonal antibodies were found to be cross reactive to a contaminant in 
the Western blots, none of the antibodies from NeoClone were tested in the pseudovirus 
neutralization assay. Instead, the assay was performed as a proof of concept using sera from mice 
injected with purified HPV45 L1 capsomeres with alum. Sera was taken from the mice at day 21 
and day 35 day after initial injection of a low dose (LD) or a high dose (HD) of HPV45 L1 
capsomeres. Reactivity for the sera was determined by the difference between the anti BPV 
value and each antibody value, divided by the difference between the anti BPV value and the 
heparin value. Percent neutralization, 100 x the fractional neutralization value, was determined 
and plotted for the six serial dilutions of the antibodies (Figure 4).  
The HD sera obtained after 35 days had the highest percent neutralization. The HD sera 
obtained after 21 days and the LD sera obtained after 35 days had similar percent neutralizations 
that were lower than the HD, day 35 sera. The lowest percent neutralization was seen in the LD 
sera obtained after 21 days.  
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4. Discussion  
  The results from the Western Blots provide strong evidence that these monoclonal 
antibodies were produced to a contaminant in the purified HPV45 L1 protein. The source of this 
contaminant is unknown; it could have occurred during protein purification or production of the 
monoclonal hybridomas by NeoClone. Regardless of the source, the contamination dramatically 
limited the analysis and use of these 42 antibodies. Although none of the antibodies are 
candidates for use in further ELISAs, Western blots or Pseudovirus neutralization assays, the 
data from this research has provided a proof of concept for the characterization of monoclonal 
antibodies for HPV45 L1.  
 ELISA testing was used to determine which monoclonals were reactive to 
conformationally intact HPV45 L1 bound to a plate. In the ELISAs, four monoclonal antibodies 
(1H6D7, 1H6B9, 1H7C10 and 1H7D12) were classified as strongly reactive with absorbance’s 
greater than 2 RAU.  Six monoclonal antibodies had an absorbance between 1 RAU and 2 RAU 
and were determined to be moderately reactive. Five antibodies had an absorbance between 0.5 
RAU and 1 RAU and were classified as weakly reactive.  
 Western blotting was used to determine which antibodies were reactive to denatured 
HPV45 L1 protein. A coomassie gel run prior to initiation of the Western blots showed that the 
HPV45 L1 protein is ~55 kDa. No other bands appeared in this coomassie gel, indicating that the 
initial purified HPV45 L1 protein sent to NeoClone for antibody production was 
uncontaminated. None of the 40 monoclonal antibodies tested reacted with the HPV45 L1 
protein at ~55 kDa. Three monoclonal antibodies (7B1H8, 7B1E8 and 2B8B11) reacted with an 
unknown protein at ~100 kDa. A band at ~100 kDa was also present in the BLR lysate and 
BLR+plasmid for 2 of the monoclonals. In addition, 4 of the monoclonal antibodies (4E6H11, 
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4E6G12, 5H5C11 and 5H5D8) reacted with an unknown protein at <55 kDa. A band at <55 kDa 
was also present in the BLR lysate and BLR+plasmid in 17 of the Western blots. Interestingly, 
the ~100 kDa and the <55 kDa bands were not visible in the coomassie gel. The lack of 
reactivity with denatured HPV45 L1 protein indicates that the antibodies were reacting to cross 
contaminants instead of HPV45 L1 protein. Because the Western results revealed monoclonal 
antibody reactivity with contaminants, we can extrapolate that the monoclonal antibodies found 
to be reactive in the ELISAs were also reacting to contaminants, not to HPV45 L1.  
 An interesting finding worth noting is that the monoclonals found to be strongly or 
moderately reactive in the ELISAs were not strongly reactive in the Western blots. Only two 
antibodies (4E8B12 and 7B1H8) that were weakly reactive in the ELISA also showed reactivity 
in the Westerns. This difference is due to the structural integrity of the proteins in the assays. In 
ELISA, the protein’s natural conformation is preserve whereas the proteins used in Western blots 
are denatured by SDS in order to migrate through the acrylamide gel effectively. These 
differences in the structure of the proteins cause different epitopes to be exposed that are not 
normally recognized by the same antibody. This difference shows the necessity for a 
characterization project; the antibodies that are useful in ELISAs might not be useful in Western 
blots.  
 The pseudovirus neutralization assay is another useful test in monoclonal antibody 
characterization because it evaluates how effectively antibodies recognize a conformationally 
accurate HPV45 L1 viral capsid in solution. In this assay, monoclonal antibodies are mixed with 
pseudoviruses containing SEAP plasmids and incubated with 293T augmented cells for 72 hours. 
During this incubation, any pseudoviruses that are not neutralized by the antibodies are able to 
infect the cells. The secreted alkaline phosphatase (SEAP) plasmids includes an SV40 origin 
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sequence so its expression is initiated by SV40 Large T Antigen in the 293T cells. The secretion 
of SEAP from the cells into the media is measured using a chemiluminescent reporter system. 
Antibodies with a strong affinity for the pseudovirus will neutralize and prevent pseudovirus 
entry, therefore decreasing the SEAP expressed from the cells. Titrating each monoclonal shows 
the overall efficacy of each antibody: antibodies capable of high neutralization at low 
concentrations are more effective at recognizing fully formed virus capsids, making them ideal 
antibodies for use in vaccine development. Although the pseudovirus neutralization assay 
performed in this study did not test any monoclonal antibodies, its success proved the importance 
of this assay in future characterization studies of monoclonal antibodies.  
 
5. Conclusion 
 The HPV vaccines that are currently on the market are not accessible in many parts of the 
world where they are needed the most. The high cost of producing vaccines in eukaryotic cell 
systems and the need for cold chain transport severely limit the use of current vaccines in 
developing countries. Second generation vaccines produced with lyophilized HPV L1 
capsomeres are less expensive and thermodynamically stable without loss of efficacy. In order to 
control the quality of these vaccines and produce them on a large scale, monoclonal antibodies 
specific to each HPV serotype in the vaccine are necessary. Out of the four HPV serotypes in the 
second generation HPV vaccine that the Garcea lab is developing, only HPV45 lacked unique 
monoclonal antibodies. The focus of this project was to characterize monoclonal antibodies 
developed by NeoClone toward purified HPV45 L1protein in order to determine antibodies that 
could be used in ELISAs, Western blots and pseudovirus neutralization assays, three assays that 
are crucial to the vaccine development and production process.  
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 Although the monoclonal antibodies were made to a cross contaminant instead of HPV45 
L1, this project serves as a proof of concept for the characterization of HPV45 L1 monoclonal 
antibodies. The characterization of these antibodies in future projects will allow for better quality 
control and faster production of a second generation tetravalent HPV vaccine that is low cost and 
thermodynamically stable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morgan 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. HPV45 L1 monoclonal antibody ELISA absorbance data. Each monoclonal antibody was run with three dilutions of 
HPV45 L1 protein: 0.25 ug/well, 0.13 ug/well, 0.06 ug/well. The plate reader was set at 450nm wavelength end point 
absorbance.  
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Fig. 2. Compilation of Western blots for HPV45 L1 monoclonal antibodies. See fig. 1 
for assay layout. Not included are the blots that did not have discernable banding. 
55 kD 
Fig. 3. A. Coomassie gel with the five proteins evaluated in the Western blots. B. Layout of HPV45 monoclonal antibody 
Western blot using anti L1 as the primary antibody. The 55 kD band in lane one depicts the size of the HPV45 L1 protein.       
C. Western blot using the Gardasil antibody which identifies HPV45 L1 and HPV16 L1.  
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Fig. 4. Proof of concept pseudovirus neutralization assay data. Four samples of sera obtained from mice injected with 
liquid HPV45 L1 protein were run over six serial dilutions. Percent neutralization values were generated by comparing 
luminescence values of the antibody wells to a positively neutralizing heparin control.  
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